This study provides the first comprehensive estimation of the lifetime risk (LTR) of digestive system cancers in China using the Global Burden of Disease (GBD) 2023 data. With a 11.36% LTR for incidence and 8.28% for mortality, the findings highlight a profound public health challenge. Significant male-to-female and regional disparities—particularly the high burden in East China—underscore the urgent need for geographically tailored screening programs and primary prevention to mitigate this escalating health threat.

A programmable microfluidic device developed at Institute of Science Tokyo, Japan, combines deterministic lateral displacement, a microfluidic technique that is used to separate particles according to their size, with temperature-responsive polymer micropillars to dynamically change the separation conditions along a single channel. Using this device, the researchers successfully separated multiple particle populations. Additionally, they efficiently isolated viable cancer cells, white blood cells, and red blood cells from diluted whole blood.

Laparoscopic gastrectomy is a well-established but technically demanding treatment against gastric cancer. Robotic gastrectomy, developed to overcome these limitations, has gained popularity in Japan since national health insurance coverage began in 2018. This study comparing matched patient pairs treated between 2023–2024 found that robotic gastrectomy reduced blood loss, conversions to open surgery, and hospital stays. Robotic distal gastrectomy also lowered complications and infections, supporting adoption to improve outcomes with minimally invasive surgery in Japan.

Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the University Hospital Bonn and the University of Bonn in collaboration with Prof. Robert P. Fisher of the Icahn School of Medicine at Mount Sinai, New York, and has now been published in Nature Reviews Drug Discovery.